Ionis Pharmaceuticals Inc... (IONS)
28.99
1.09 (3.91%)
At close: Apr 14, 2025, 3:38 PM
3.91% (1D)
| Bid | 28.94 |
| Market Cap | 4.61B |
| Revenue (ttm) | 705.32M |
| Net Income (ttm) | -453.9M |
| EPS (ttm) | -3.04 |
| PE Ratio (ttm) | -9.54 |
| Forward PE | -12.36 |
| Analyst | Buy |
| Ask | 29.06 |
| Volume | 1,763,785 |
| Avg. Volume (20D) | 1,784,819 |
| Open | 28.46 |
| Previous Close | 27.90 |
| Day's Range | 27.82 - 29.02 |
| 52-Week Range | 23.95 - 52.34 |
| Beta | 0.29 |
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various...
Industry Biotechnology
Sector Healthcare
IPO Date May 17, 1991
Employees 1,069
Stock Exchange NASDAQ
Ticker Symbol IONS
Website https://www.ionispharma.com
Analyst Forecast
According to 18 analyst ratings, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $59.5, which is an increase of 105.24% from the latest price.
Stock ForecastsNext Earnings Release
Ionis Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-7.76%
Shares of pharmaceutical and healthcare stocks are...
Unlock content with
Pro Subscription
7 months ago
-12.29%
Ionis Pharmaceuticals shares are trading lower after the company priced its $500.3 million public offering of 11.5 million common shares at $43.50 per share.
